GTx, Inc. (GTXI) Presents on Enobosarm for the Prevention and Treatment of Muscle Wasting in Cancer Patients at the 2013 MASCC/ISOO International Symposium on Supportive Care in Cancer
6/28/2013 9:25:57 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
GTx, Inc. (Nasdaq: GTXI) announced today that the Company showcased two scientific poster presentations on enobosarm, a selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in cancer patients during the 2013 MASCC/ISOO International Symposium on Supportive Care in Cancer being held at the InterContinental Convention Centre in Berlin, Germany, June 27-29, 2013.
Help employers find you! Check out all the jobs and post your resume.